Hims & Hers Health (NYSE:HIMS) Stock Price Down 2.7%

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) dropped 2.7% during mid-day trading on Friday . The stock traded as low as $17.03 and last traded at $17.23. Approximately 1,372,400 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 7,671,661 shares. The stock had previously closed at $17.71.

Analyst Upgrades and Downgrades

HIMS has been the subject of several recent analyst reports. TD Cowen upped their target price on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Jefferies Financial Group upped their price objective on Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, June 27th. Deutsche Bank Aktiengesellschaft upped their price objective on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Bank of America dropped their price objective on Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, September 13th. Finally, Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $19.86.

Hims & Hers Health Price Performance

The stock has a market cap of $3.77 billion, a P/E ratio of -1,771.00 and a beta of 1.05. The firm’s fifty day moving average price is $16.96 and its two-hundred day moving average price is $17.13.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $315.65 million for the quarter, compared to analysts’ expectations of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The firm’s revenue was up 51.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.03) earnings per share. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In other news, insider Michael Chi sold 9,313 shares of the firm’s stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $22.00, for a total transaction of $204,886.00. Following the transaction, the insider now directly owns 185,326 shares of the company’s stock, valued at $4,077,172. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Michael Chi sold 9,313 shares of the firm’s stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $22.00, for a total transaction of $204,886.00. Following the transaction, the insider now directly owns 185,326 shares of the company’s stock, valued at $4,077,172. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $20.75, for a total transaction of $3,919,426.00. Following the sale, the chief executive officer now owns 33,502 shares of the company’s stock, valued at $695,166.50. The disclosure for this sale can be found here. Insiders have sold a total of 731,473 shares of company stock valued at $12,671,277 over the last 90 days. 17.71% of the stock is owned by insiders.

Institutional Trading of Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC lifted its holdings in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the last quarter. Quest Partners LLC lifted its holdings in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares during the last quarter. Van ECK Associates Corp purchased a new position in shares of Hims & Hers Health during the second quarter valued at approximately $111,000. Amalgamated Bank increased its position in shares of Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after acquiring an additional 2,354 shares in the last quarter. Finally, Daiwa Securities Group Inc. bought a new stake in shares of Hims & Hers Health during the second quarter valued at approximately $142,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.